Pfizer made 6m courses of Covid pill, hitting Q1 target
Add BT as a preferred source
DeeperDive is a beta AI feature. Refer to full articles for the facts.
[NEW JERSEY] Pfizer said on Monday (Apr 4) it made 6 million courses of its antiviral Covid-19 pill Paxlovid in the first quarter, hitting a target set by chief executive Albert Bourla.
Pfizer spokesperson Sharon Castillo said in an email that the company has shipped the pills to over 26 countries so far.
Bourla has said the company expects to produce at least 120 million courses of the drug this year, with 30 million of those courses coming in the first half.
The US government has bought 20 million of those courses, with the first 10 million expected to be delivered by the end of June. Around 1.4 million courses have been distributed in the United States so far.
Paxlovid is expected to be an important tool in the fight against Covid-19 after it reduced hospitalisations in high-risk patients by around 90 per cent in a clinical trial. The results were significantly better than those for Merck & Co's rival antiviral pill molnupiravir in its clinical trial. REUTERS
Decoding Asia newsletter: your guide to navigating Asia in a new global order. Sign up here to get Decoding Asia newsletter. Delivered to your inbox. Free.
Share with us your feedback on BT's products and services
TRENDING NOW
‘Boring’ is the new black: The stars are aligning for a Singapore stock market revival
Near sell-out launches in March boost developer sales to 1,300 units after four slow months
China pips the US if Asean is forced to choose, but analysts warn against reading it like a sports result
Genting Singapore’s Lim Kok Thay receives S$7.5 million pay package for FY2025
